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Abstract
Early detection of cancer has great clinical importance and potentially improves cure, survival rate and treatment outcome. RNA
editing technology can be used as targeted and precise molecular scissors to cut and replace disease-causing genes with healthy
ones. This is a post transcriptional modification that can lead to the recoding of proteins. RNA editing technology is in its infancy,
but it can be used for early diagnoses and effective treatment of cancer. The full potential of precision medicine will be achieved by
using the knowledge of RNA reversible-recoding to edit the protein. RNA editing technology could be used to expose chemo
resistant cancer cells, dormant cancer stem cells and other malignant tumors. RNA editing generates RNA and protein diversity
to accelerate and enhance the screening window for early detection of cancer. We propose that the RNA editing sites could be
used as a novel tool for early detection of cancer.
RNA Editing and Clinical Applications
Cancer is one of the leading causes of death worldwide.1 There
is currently no cure and early detection of cancer offers the
opportunity for greater treatment outcome and cure.1 Innova-
tive new technologies are being developed to aid in the early
detection of cancer and treatment.1-3 The use of RNA editing
technology for prediction, diagnostics and treatment of cancer
is expected to enable more precise, and preventive clinical
care.4-6 The RNA editing platform enables discrimination
between normal and cancerous cells (Figure 1).4,7,8
Researchers are focusing on the development of RNA editing
sites, which has the potential to detect cancer at early stage.9,10
Published studies have indicated the role of ADAR2 (adenosine
deaminase acting on RNA 2) and APOBEC1 (apolipoprotein B
mRNA editing catalytic subunit 1) in cancer detection, and their
use in predicting the survival of cancer patients.5,6 The ADAR1
and 2 are part of the spliceosome, which is expected to regulate
effectiveness of RNA editing and splicing machinery.11 ADAR2
is also able to edit its own precursor mRNA to generate new
splicing sites, control stability and decision-making process of
other editing sites.7 ADAR enzymes target non-coding micro-
RNAs (miRNAs), which can be used not only to correct tumor-
specific mutations but also to expose tumors antigens to immune
system.11 Mis-regulated RNA editing can promote the progres-
sion and metastasis of cancers.7 For example, antizyme inhibitor
1 (AZIN1) is overexpressed in hepatocellular carcinoma. In
cancer development misguided ADAR2 suppresses immune
sensors (MDA5 and PKR), thereby promoting tumor growth.5,11
Correctly regulated editing sites by ADAR2, activates the
immune system and leads to suppression of tumors.5 Clinically
relevant editing sites could be identified and can be used for
early detection of cancer.7 For instance, editing site I342M can
be used for detection of breast cancer and editing site S367G can
be used for diagnosis of hepatocellular cancer.5,11 APOBECs are
well known for their ability to edit proteins and miRNAs in
different diseases and cancer.12,13 APOBEC1 protein regulate
hypermutations in cancers and might affect expression levels
of cancer genes.12,14 APOBEC1 expression has been linked to
cancer and could be used for early detection of cancer.5,12 For
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instance, unregulated RNA editing of APOBEC1 induce somatic
mutations in esophageal cancer.12,13 The discovery of APO-
BEC1, together with its cofactor RBM47, has led to the
identification and validation of hundreds of RNA editing
sites, which can regulate the immune system.5,13 Cytosine
to uracil (C-to-U) editing, mediated by APOBEC1, is an
important new avenue to be studied and may promote a
more aggressive phenotype in cancer progression.13 The use
of new technologies such as RNA editing and imaging tech-
niques have significantly improved, early interventions for
cancer.2,4 The improvement of RNA editing technology
allows detecting cancer sooner for more precise prediction
and treatment of cancer with greater specificity.5
Genome editing technologies are rapidly emerging and
becoming more important in clinical and translational medi-
cine.4,5 RNA editing, the post-transcriptional recoding of RNA
molecules, has the potential to ultimately elucidate biological
mechanisms behind disease development and progression.4-6
Clinical trials of RNA editing therapy are on the way to evaluate
for its efficacy in different diseases and especially for cancer.4-6
The genome contains all the necessary information that dictates
cellular processes and physiological functions.15 RNA editing is
an important stepping stone for clinicians to learn more about
cellular processes of cancer.15 RNA editing technology plays an
important role in fine-tuning biological function and opens novel
opportunities to treat many diseases including cancer.4,15
Whether clinical trials of cancer treatment succeed or fail,
we need to reevaluate the lessons learned from previous trials
and it is essential to understand the biological concept of RNA
editing when moving forward toward the clinics.14,15 In the
flow of genetic information from DNA to protein, RNA works
as a messenger between DNA and protein.8,15 RNA receives
the DNA-dictated message and sends it further for protein pro-
duction.14 Due to its central role in biological information,
RNA editing technology has attracted much excitement to fix
mutated genes in cancer and treat other diseases by fixing
faulty genes by recoding of nucleotide sequence (Figure 1).4,5,14
RNA editing is reversible, and by reprogramming editing sites
it is possible to rewrite the gene information.10,14 Unlike DNA
editing and CRISPR technology, which is permanent for gen-
ome editing, the effects of RNA editing are reversible and
temporary.14,16 This technology opens a new gateway for treat-
ing temporary conditions of pain, inflammation, and permanent
condition of gene mutation and other diseases.14,16 Scientists
are developing novel RNA editing therapies by designing new
RNA editors, and engineering new molecules that guide editor
enzymes to specific edit sites.4,16
Emerging Technology of RNA Editing
RNA is a working copy of DNA that acts as a messenger to
carry information between DNA and the cellular machinery to
Figure 1. Schematic diagram of RNA editing technology in early detection of cancer and other diseases.
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make proteins (Figure 1).1,15,17 Many genetic diseases are
caused by mutations in RNA, therefore scientists recently
developed RNA Editing for Programmable A to I Replace-
ment (REPAIR) system to test whether editing technology can
be used to fix such mutations.17 The REPAIR system has the
ability to recognize, cut and edit RNA sites.17 It could open up
new therapeutic options for early detection of cancer and other
diseases by enabling recoding of RNA and then rewriting the
protein to correct the faulty sites.4,15 The ability to correct
disease-causing mutations by efficient and precise recoding is
one of the primary goals of RNA editing.15,17 Recent studies
have associated RNA editing with cancer development which
can be used for diagnosis and treatment of cancer.15,17 Even
though RNA editing is associated with cancer development, the
function and clinical relevance of editing in cancers have not
been well studied.5,16 This new technology opens up new
opportunities to recover the function and treat many diseases.
The new emerging platform of RNA editing would provide
biological understand of the chemo resistant cancer and possi-
bilities for re-designing new drugs.17 RNA editing could be
helpful in improving initial detection of cancer and developing
more predictive biomarkers in cancer patients. The publicly
available database of DARNED (DAtabase of RNA EDiting)
provides centralized access to available published data related
to RNA editing.4,6,17 RADAR (RNA-editing Analysis-pipeline
to Decode All twelve-types of RNA-editing events) is another
database to detect and visualize RNA editing events.8,17 EDK
(Editome Disease Knowledgebase) can be used to identify
RNA targets, editing sites, associated proteins, and other inter-
mediate regulators, suppressors and activators for RNA-editing
machinery.11,18 EDK is as an open access resource and is help-
ful to understand editome-disease associations and the regula-
tors of RNA editing machinery.18 These databases have been
designed for researchers seeking information on RNA editing
and can be used for bioinformatic hunting to search and iden-
tify RNA editing sites in different diseases. RNA editing can be
used to fix the genetic mutation in cancer.5,7,9 None of the RNA
editors are perfect yet.14 It is also unknown whether mis-
regulation of RNA editing in a particular disease is a cause
or a consequence. However, the designing of new drugs based
on RNA editing technology, will only contribute to curing the
disease if mis-regulation is the cause.18 Understanding the pre-
cise role of RNA editing remains a challenge and needs further
study to explore its role in different diseases.
Conclusions
Reprogrammable RNA editing technology has the potential to
reversibly recode and rewrite the RNA information for research
and disease treatment.15,17 RNA editing can be used to unravel
dormant cancer stem cells that often escape chemothera-
pies.9,10,14 In this way RNA editing could be used to target
therapeutic resistance and tumor relapse. We propose that
engineered-guided-RNAs that bind ADAR and direct it to fix
RNA mutations would bring new opportunities to identify can-
cer biomarkers at early stage.10,14,19 Using RNA editing sites as
a tool, many early events in cancer progression can be identi-
fied.4,17 Understanding the precise role of RNA editing remains
a challenge and needs further study to explore its role further.
Still, many open questions remain. For instance, Do ADARs
contribute to human diseases independently of RNA editing? Is
it possible to target and correct RNA misediting sites? How do
editor enzyme-sensors distinguish between good and bad sites?
How many RNA editing sites are transferred to next genera-
tion? Although there are considerable hurdles to overcome, we
will likely see RNA editing technology in clinical trials in the
future as a novel therapeutic approach.
Future Directions and Challenges
RNA editing is currently changing the frontiers of medicine
and offers benefits over genome and germline gene editing,
which alters the genome at its earliest stages, and may affect
every cell of the organism.15,17 The ability to predict and diag-
nose cancer at an early stage, the RNA editing can achieve this
with lower error and more precision, although the technology is
certainly not yet perfect.17 Along with ethical concerns there is
no clear consensus as to whether RNA editing is just an incre-
mental step or disruptive step moving forward for clinical
translation.7,17 RNA editing is a very powerful strategy for
precise manipulation of cells but it requires further study to
overcome the difficult technical challenges of editing sites and
editor enzymes.17 There are certainly potential benefits, risks
and harms associated with this technology. The biosensing and
bioengineering are new approaches that can improve this tech-
nology further by designing new editor enzymes that target
RNA, and can be used to correct faulty proteins in different
diseases, genetic and non-genetic conditions.10,17
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to
the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, author-




1. Ullah M, Akbar A, Ng NN, Concepcion W, Thakor AS. Mesench-
ymal stem cells confer chemoresistance in breast cancer
via a CD9 dependent mechanism. Oncotarget. 2019;10(37):
3435-3450.
2. Ullah M, Akbar A, Thakor AS. An emerging role of CD9 in
stemness and chemoresistance. Oncotarget. 2019;10(40):
4000-4001.
3. Ullah M. Need for specialized therapeutic stem cells banks
equipped with tumor regression enzymes and anti-tumor genes.
J Biomed Allied Res. 2020;2(1):1-6.
Ullah et al 3
4. Ullah M, Akbar A. Clinical relevance of RNA editing to early detec-
tion of cancer in human. Int J Stem Cell Res Ther. 2020;7(1):066.
5. Goncharov AO, Kliuchnikova AA, Nasaev SS, Moshkovskii SA.
RNA editing by ADAR adenosine deaminases: from molecular
plasticity of neural proteins to the mechanisms of human cancer.
Biochemistry (Mosc). 2019;84(8):896-904.
6. Kiran A, Baranov PV. DARNED: a database of RNA editing in
humans. Bioinformatics. 2010;26(14):1772-1776.
7. Asaoka M, Ishikawa T, Takabe K, Patnaik SK. APOBEC3-mediated
RNA editing in breast cancer is associated with heightened immune
activity and improved survival. Int J Mol Sci. 2019;20(22):5621.
8. Ramaswami G, Li JB. RADAR: a rigorously annotated database
of A-to-I RNA editing. Nucleic Acids Res. 2014;42(Database
issue):D109-D113.
9. Tang SJ, Shen H, An O, et al. Cis- and trans-regulations of pre-
mRNA splicing by RNA editing enzymes influence cancer devel-
opment. Nat Commun. 2020;11(1):799.
10. Qian M, Spada C, Wang X. Detection and application of RNA
editing in cancer. Adv Exp Med Biol. 2018;1068:159-170.
11. Jain M, Jantsch MF, Licht K. The editor’s I on disease develop-
ment. Trends Genet. 2019;35(12):903-913.
12. Saraconi G, Severi F, Sala C, Mattiuz G, Conticello SG. The RNA
editing enzyme APOBEC1 induces somatic mutations and a com-
patible mutational signature is present in esophageal adenocarci-
nomas. Genome Biol. 2014;15(7):417.
13. Rayon-Estrada V, Harjanto D, Hamilton CE. Epitranscriptomic
profiling across cell types reveals associations between
APOBEC1-mediated RNA editing, gene expression outcomes,
and cellular function. Proc Natl Acad Sci U S A. 2017;114(50):
13296-13301.
14. Kung CP, Maggi LB, Jr, Weber JD. The role of RNA editing in
cancer development and metabolic disorders. Front Endocrinol
(Lausanne). 2018;9:762.
15. Song C, Sakurai M, Shiromoto Y, Nishikura K. Functions of the
RNA editing enzyme ADAR1 and their relevance to human dis-
eases. Genes (Basel). 2016;7(12):129.
16. Vogel P, Stafforst T. Critical review on engineering deaminases
for site-directed RNA editing. Curr Opin Biotechnol. 2019;55:
74-80.
17. Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications
of genome editing technology in the targeted therapy of human
diseases: mechanisms, advances and prospects. Signal Transduct
Target Ther. 2020;5:1.
18. Niu G, Zou D, Li M, et al. Editome Disease Knowledgebase
(EDK): a curated knowledgebase of editome-disease associations
in human. Nucleic Acids Res. 2019; 47(D1):D78-D83.
19. Ullah M, Qiao Y, Concepcion W, Thakor AS. Stem cell-derived
extracellular vesicles: role in oncogenic processes, bioengineer-
ing potential, and technical challenges. Stem Cell Res Ther. 2019;
10(1):347.
4 Technology in Cancer Research & Treatment
